Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3056% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 43.8Yield 5.61%
Pfizer Genotropin (somatropin by Quarter
Genotropin (somatropin — growth hormone) — Worldwide reported YoY (%) (%)
Pfizer Genotropin (somatropin: -11.0% in Q2 2026, down 1.0 pts from a year earlier.
Latest, Q2 2026
-11.0%
Period ended Jun 28, 2026
Change on a year earlier
-1.0 pts
-10.0% in Q2 2025
History
33 quarters
Since Q4 2017
Sources
33
Documents cited below
Where the Q2 2026 figure comes from
“|| Genotropin | 94 | 106 | (11%) | (15%) | 2 | 18 | (89%) | 92 | 89 | 4% | —”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Genotropin (somatropin (%), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/genotropin-yoy-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.
See a number that looks wrong?